Scott Gale, executive director for Halliburton Labs, has died, leaving behind a legacy of innovation, collaboration, and curiosity. Photo via Rice University

Houston energy and innovation leader Scott Gale died on September 24 after a years-long fight with cancer. He was 40 years old.

Gale was the inaugural executive director for Halliburton Labs, which launched in 2020. Prior to that role, he lead global strategy initiatives for Halliburton. A Brigham Young University graduate, he received his MBA from Rice University in 2019, where he co-founded the Jones Student Association for Executives. After his graduation, he served on the the Rice Business Alumni Association Board and the Energy Advisory Board for the Rice Alliance Clean Energy Accelerator.

"Scott made an impact with his incredible kindness, energy, and talent," Dale Winger, managing director at Halliburton Labs, tells InnovationMap. "Scott was passionate about his family, his friends, his community, and his work. He provided incredible creativity and drive to bring Halliburton Labs to life within Halliburton, and despite a terrible cancer diagnosis, Scott continued to collaborate and build connections that launched the inaugural Houston Energy and Climate Startup Week. Work and play were always fun with Scott. His generosity and dedication to strengthen the Houston innovation ecosystem will be missed, yet his legacy endures.”

Gale was also a voice actor and the co-host of two podcasts: Rice University's Owl Have You Know Podcast, which shares experiences of Rice's business community, and the Curiosity podcast, which explored optimism and curiosity with guests and co-host Brad Rossacci.

"A rebellious optimist at his core, Scott believed we need a biased toward action, a mission focused belief system, and a healthy dose of rebellion for good measure," Rossacci, who serves as creative director at Accenture, says. "Carving his own path in the universe, Scott discovered his life’s work and unceasingly committed himself to helping humanity deepen their curiosity, building connective tissue across society, and advancing the future of energy on the shoulders of the giants who came before him. Ultimately, fulfilling his infinite ambitions and creating an echo that will reverberate in the cosmos for eternity."

One month ago, he stepped away from his role at Halliburton Labs, sharing his cancer journey in a message shared on LinkedIn. In the post, he encouraged his whole community to "go out and live a life that echoes," and ended with "onward," something Gale regularly imparted when he spoke on progress within energy and innovation.

Earlier this month during the Houston Energy and Climate Startup Week, which Gale was instrumental in creating but unable to attend due to the progression of his illness, the Energy Tech Nexus awarded its Nexus Community Award to Gale, and his father, Andrew Gale, accepted the award on his behalf.

"He is very focused on the community in Houston and the tech industry," Andrew Gale said about his son when accepting the award, "he feels so honored to be given the opportunity to be able to have an influence."

In addition to his father and his mother, JoAnna, Scott is survived by his wife of 18 years, Nicole, and their four children, as well as his seven siblings — Siara, Shanna, Spencer, Seth, Shalya, Sam, and Shane. In honor of his brother, Sam launched a GoFundMe campaign for his nieces and nephew's education, and donations are currently being accepted.

In his obituary, his family shared something Scott regularly said as he battled his cancer with countless hospital visits and experimental treatments: “I’m not a doctor, but I’m pretty sure if you die, the cancer dies at the same time. That’s not a loss. That’s a draw.”

Earlier this year, he joined the Houston Innovators Podcast to discuss Houston Energy and Climate Startup Week and call for collaboration within the ecosystem.


Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Axiom Space-tested cancer drug advances to clinical trials

mission critical

A cancer-fighting drug tested aboard several Axiom Space missions is moving forward to clinical trials.

Rebecsinib, which targets a cancer cloning and immune evasion gene, ADAR1, has received FDA approval to enter clinical trials under active Investigational New Drug (IND) status, according to a news release. The drug was tested aboard Axiom Mission 2 (Ax-2) and Axiom Mission 3 (Ax-3). It was developed by Aspera Biomedicine, led by Dr. Catriona Jamieson, director of the UC San Diego Sanford Stem Cell Institute (SSCI).

The San Diego-based Aspera team and Houston-based Axiom partnered to allow Rebecsinib to be tested in microgravity. Tumors have been shown to grow more rapidly in microgravity and even mimic how aggressive cancers can develop in patients.

“In terms of tumor growth, we see a doubling in growth of these little mini-tumors in just 10 days,” Jamieson explained in the release.

Rebecsinib took part in the patient-derived tumor organoid testing aboard the International Space Station. Similar testing is planned to continue on Axiom Station, the company's commercial space station that's currently under development.

Additionally, the drug will be tested aboard Ax-4 under its active IND status, which was targeted to launch June 25.

“We anticipate that this monumental mission will inform the expanded development of the first ADAR1 inhibitory cancer stem cell targeting drug for a broad array of cancers," Jamieson added.

According to Axiom, the milestone represents the potential for commercial space collaborations.

“We’re proud to work with Aspera Biomedicines and the UC San Diego Sanford Stem Cell Institute, as together we have achieved a historic milestone, and we’re even more excited for what’s to come,” Tejpaul Bhatia, the new CEO of Axiom Space, said in the release. “This is how we crack the code of the space economy – uniting public and private partners to turn microgravity into a launchpad for breakthroughs.”

Chevron enters the lithium market with major Texas land acquisition

to market

Chevron U.S.A., a subsidiary of Houston-based energy company Chevron, has taken its first big step toward establishing a commercial-scale lithium business.

Chevron acquired leaseholds totaling about 125,000 acres in Northeast Texas and southwest Arkansas from TerraVolta Resources and East Texas Natural Resources. The acreage contains a high amount of lithium, which Chevron plans to extract from brines produced from the subsurface.

Lithium-ion batteries are used in an array of technologies, such as smartwatches, e-bikes, pacemakers, and batteries for electric vehicles, according to Chevron. The International Energy Agency estimates lithium demand could grow more than 400 percent by 2040.

“This acquisition represents a strategic investment to support energy manufacturing and expand U.S.-based critical mineral supplies,” Jeff Gustavson, president of Chevron New Energies, said in a news release. “Establishing domestic and resilient lithium supply chains is essential not only to maintaining U.S. energy leadership but also to meeting the growing demand from customers.”

Rania Yacoub, corporate business development manager at Chevron New Energies, said that amid heightening demand, lithium is “one of the world’s most sought-after natural resources.”

“Chevron is looking to help meet that demand and drive U.S. energy competitiveness by sourcing lithium domestically,” Yacoub said.

---

This article originally appeared on EnergyCapital.